Coadministration of anti-PD-1, anti-PD-L1 and anti-CTLA-4 antibodies or treatment of anti-PD-1/PD-L1/CTLA-4 trispecific antibodies may be candidate approaches to completely unleash innate and adaptive immunity to eradicate tumors, which also fits well with cancers with PD-1+ tumor or myeloid cells. Here, PDCD1 is linked to cancer.